Target to Lead Selection for ADCs and Biologics

Accelerating Though the Drug Discovery Pipeline With ADCs

Navigating the complexities of ADC development—such as poor therapeutic windows, tumor heterogeneity, and off-tumor effects—requires precise target and lead selection. Crown Bioscience, with the largest library of patient-derived systems, including PDX models and organoids, provides unmatched target validation. Advanced engineering capabilities, including the creation of isogenic pairs and resistant models, optimize ADCs for greater efficacy.

Through detailed tissue analysis using digital pathology and spatial biology, we identify key biomarkers that enhance therapeutic windows and reduce toxicity. By integrating these proven methods with innovative screening techniques, Crown Bioscience ensures a strong foundation for ADC project success, accelerating your path to clinical validation.

Bundled Solutions

Choose from flexible full end-to-end solutions OR customizable bundled services. Our three bundles meet you at the right timepoint in your target to lead selection journey. Choose the Proof of Concept bundle for your Antibody Discovery stages. Choose the Optimization Bundle for your lead optimization stages. Or, take it further into candidate confirmation and IND with the Premium Efficacy Bundle.

Blog

How to Enhance Precision in Target and Lead Selection for Biologics

I want to know more

Journey through the drug discovery pipeline from target discovery to in vivo pharmacology. Along the way, take advantage of the Largest biobank of patient-derived models, Model development capabilities, Cell-based assays for Screening ADCs, and advanced downstream analysis. Enter in at any point of your journey.

Our Customers Love Us

We are proud to boast the best Customer Experience in the Industry, explore our data below.

Studies
Completed

This data point indicates the total number of studies in Q2 2023 that the CSAT, Customer Effort, and Customer Expectation scores are measured against.

Studies
Completed